Metastatic Cancer

A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Harvesting Cells for Experimental Cancer Treatments

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Biomarkers of Immune-Related Toxicity

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

SLV-154 Treatment of Advanced Cancers

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer